Connection

Michael Hallek to Disease-Free Survival

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Disease-Free Survival.
Michael Hallek
Connection Strength
0.562
Disease-Free Survival
  1. Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials. Anticancer Res. 2019 May; 39(5):2591-2598.
    View in: PubMed
    Score: 0.132
  2. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018 03 01; 131(9):955-962.
    View in: PubMed
    Score: 0.120
  3. Role and timing of new drugs in CLL. Hematol Oncol. 2017 Jun; 35 Suppl 1:30-32.
    View in: PubMed
    Score: 0.116
  4. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14; 127(2):208-15.
    View in: PubMed
    Score: 0.103
  5. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br J Haematol. 2018 12; 183(5):727-735.
    View in: PubMed
    Score: 0.032
  6. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017 12; 31(12):2833-2837.
    View in: PubMed
    Score: 0.029
  7. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 09 21; 130(12):1477-1480.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.